Federal Supreme Court upholds its stricter Pfizer case law

In its last week's published decisions (2C_145/20182C_147/2018), the Federal Supreme Court upheld its stricter case law on the permissibility of price recommendations and vertical price agreements thereby confirming its Pfizer practice (Lenz & Staehelin Update NewsflashKluwer Competition Law Blog).

Marcel Meinhardt and his team represent Pfizer before the Competition authorities.

Published: 1 November 2021